A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 10, 1996, Pages 3535-3539

  Laue, Louisa ^a,c   Merke, Deborah P ^a,d   Jones, Janet V ^a,d   Barnes, Kevin M ^a   Hill, Suvimol ^b   Cutler Jr , Gordon B ^a,d  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^d USPHS ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORELIN; FLUDROCORTISONE; FLUTAMIDE; HYDROCORTISONE; HYDROXYPROGESTERONE; TESTOLACTONE;

ARTICLE; BONE MATURATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GROWTH REGULATION; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERANDROGENISM; HYPERCORTISOLISM; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; ADRENOCORTICOTROPIC HORMONE; BONE DEVELOPMENT; CHILD; CHILD, PRESCHOOL; DEHYDROEPIANDROSTERONE; FEMALE; FLUTAMIDE; HUMANS; HYDROCORTISONE; INFANT; MALE; SEASONS; TESTOLACTONE; WEIGHT GAIN;

EID: 0029846160     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.10.3535     Document Type: Article

References (26)

1. Cutler Jr GB, Laue L. 1990 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 323:1806-1813.
2. Migeon CJ, Donohoue PA. 1991 Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Its molecular basis and its remaining therapeutic problems. Endocrinol Metab Clin North Am. 20:277-296.
3. New MI, Gertner JM, Speiser PW, et al. 1988 Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatr Jpn (Overseas Ed). 30(Suppl):79-88.
4. Laue L, Kenigsberg D, Pescovitz OH, et al. 1989 Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 320:496-502.
5. Smith EP, Boyd J, Frank GR, et al. 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 331:1056-1061.
6. Federman DD. 1994 Life without estrogen. N Engl J Med. 331:1088-1089.
7. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 80:3689-3698.
8. Linder B, Esteban N, Yergey AE, et al. 1990 Cortisol production rate in childhood and adolescence. J Pediatr. 117:892-896.
9. Tanner JM, Davies PS. 1985 Clinical longitudinal studies for height and height velocity for North American children. J Pediatr. 107:317-329.
10. National Center for Health Statistics, Najjar MF, Rowland M. 1987 Anthropometric reference data and prevalence of overweight, United States, 1976-80. Vital and health statistics, ser 11, no. 238. USPHS DHHS Publication (PHS) 87-1688. Washington DC. U.S. Government Printing Office.
11. Tanner JM, Whitehouse RH, Takaishi M. 1966 Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Part II. Arch Dis Childh. 41:613-635.
12. Pescovitz OH, Comite F, Cassorla F, et al. 1984 True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone releasing hormone analog. J Clin Endocrinol Metab. 58:1064-1067.
13. Zachmann M, Prader A, Kind HP, et al. 1974 Testicular volume during adolescence: cross-sectional and longitudinal studies. Helv Pediatr Acta. 29:61-72.
14. Tanner JM. 1962 Growth at adolescence. 2nd ed. Springfield: Thomas.
15. Greulich WW, Pyle SI. 1985 Radiographic skeletal development of the hand and wrist. Stanford: Stanford University Press.
16. Nieschlag E, Loriaux DL. 1972 Radioimmunoassay for plasma testosterone. Z Klin Chem Biochem. 10:164-8.
17. Odell WD, Ross GT, Rayford PL. 1967 Radioimmunoassay for luteinizing hormone in human plasma or serum: physiological studies. J Clin Invest. 46:248-255.
18. Cargille CM, Rayford PL. 1970 Characterization of antisera for human follicle-stimulating hormone radioimmunoassay. J Lab Clin Med. 75:1030-1040.
19. Kao M, Voina, Nichols A, Horton R. 1975 Parallel radioimmunoassay for plasma Cortisol and 11-deoxycortisol. Clin Chem. 21:1644-1647.
20. Schiebinger RJ, Albertson BD, Barnes KM, et al. 1981 Developmental changes in rabbit and dog adrenal function: a possible homologue of adrenarche in the dog. Am J Physiol. 240:E694-E699.
21. Chrousos GP, Schulte HM, Oldfield EH, et al. 1984 The corticotropin-releasing factor stimulation test: An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med. 310:662-666.
22. DiMartino-Nardi J, Stoner E, O'Connell A, New M. 1986 The effect of treatment on final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinol (Copenh). 279(Suppl):305-314.
23. Girard J, Baumann JB. 1977 Corticotropin-releasing hormone-adrenocorticotropin suppression by an antiandrogenic drug (cyproterone acetate): a therapeutic possibility for congenital adrenal hyperplasia. In: Lee PA, Plotnick LP, Kowarski A, Migeon CJ, eds. Congenital adrenal hyperplasia. Baltimore: University Park Press; 217-30.
24. Girard J, Baumann JB, Zuppinger K, Haas HG, Staub JJ, Wyss HI. 1978 Suppression of ACTH adrenal function by an antiandrogenic drug with weak glucocorticoid effect. In: James VHT, Serio M, Giusti G, Martini L, eds. The endocrine function of the human adrenal cortex. London: Academic Press; 289-99.
25. Wysowski DK, Friedman JP, Tourtelot JB, Horton ML. 1993 Fatal and non-fatal hepatotoxicity associated with flutamide. Ann Intern Med. 118:860-864.
26. Gomez JL, Dupont A, Cusan L, et al. 1992 Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med. 92:465-470.